TRIB TRINITY BIOTECH PLC
Debt Financing ·
The amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million.
We have not published a story on TRINITY BIOTECH yet. When there is news, it will appear here.
Trinity Biotech plc is a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Its ADSs trade on the Nasdaq Global Market under the symbol TRIB, and its principal offices are in Bray, County Wicklow, Ireland. Following its acquisition of the biosensor assets of Waveform Technologies Inc. in 2024, it is developing biosensor devices, beginning with a continuous glucose monitoring (CGM) product. Through its subsidiaries it develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments. Its products detect autoimmune, infectious and sexually transmitted diseases, disorders of the liver and intestine, and markers for diabetes. Its principal point-of-care product is Uni-Gold HIV, used for many years in sub-Saharan Africa, and its TrinScreen HIV rapid screening test received World Health Organisation approval in February 2022. Its Premier Hb9210 HbA1c analyser is CE marked and FDA cleared, and in February 2026 it became the only HbA1c analyser worldwide to receive the IFCC Gold Classification for 2026. The company sells through its own sales organisations and through distributors into approximately 100 countries.
| Product or program | What it is | Stage |
|---|---|---|
| Uni-Gold HIV | Principal point-of-care HIV test, used as a confirmatory test in Africa | |
| TrinScreen | HIV point-of-care rapid screening test | WHO approved; commercial shipments since 2023 |
| Premier Hb9210 | HbA1c analyser for monitoring diabetes and identifying pre-diabetes | CE marked and FDA cleared |
| CGM device | Continuous glucose monitoring biosensor from Waveform assets | in development |
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $61.6 million | $56.8 million |
| Research and development | $4.5 million | $4.4 million |
| Net income (loss) | -$31.2 million | -$36.9 million |
| Cash from operations | -$4.2 million | -$11.6 million |
| Cash and equivalents | $5.2 million | $3.7 million |
TRINITY BIOTECH PLC trades under the ticker TRIB on NASDAQ.
TRINITY BIOTECH PLC is listed on NASDAQ.
Our directory records TRINITY BIOTECH PLC under United States.
aibio.space lists TRINITY BIOTECH PLC among 2,820 public biotech companies and publishes its news here as stories appear.
Trinity Biotech plc is a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Its ADSs trade on the Nasdaq Global Market under the symbol TRIB, and its principal offices are in Bray, County Wicklow, Ireland.
Uni-Gold HIV: Principal point-of-care HIV test, used as a confirmatory test in Africa
TrinScreen: HIV point-of-care rapid screening test Stage: WHO approved; commercial shipments since 2023.
$61.6 million for the fiscal year ended Dec 31, 2024, as reported to the SEC.
TRINITY BIOTECH PLC reported a net loss of $31.2 million for the fiscal year ended Dec 31, 2024, and used $4.2 million of cash in operations, per its annual report to the SEC.
$4.5 million in the fiscal year ended Dec 31, 2024, per its annual report.
$5.2 million in cash at Dec 31, 2024, per its 20-F.
Our latest story on TRINITY BIOTECH, dated Aug 14, 2026: "Trinity Biotech amends Perceptive term loan, adding about $2.5 million". The amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million. Source.
Our latest debt story, dated Aug 14, 2026: "Trinity Biotech amends Perceptive term loan, adding about $2.5 million". The amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million. Source.
Press Follow on this page to add TRINITY BIOTECH to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming TRINITY BIOTECH so far, in Debt Financing.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio